Re: 6%

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

KOO-KOO2

Rank: Treasurer [?]

Points: 10765 [?]

Votes: 39 Score: 2.3 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: 6%

in response to

Re: 6%

fuzzyjr

posted on Dec 15, 2022 11:36AM

If we ever see any cash from ZCC (by either option) that would be by way of dividends should Zenith be inclined to do that?

Our only other relief is to sell our shares on the OTC the same way we are doing now. However, ZCC would be much stronger and the share price would be a lot higher than what it is today.